Research ExplorerPublicationsHigh Nr-CAM expression is associated with favorable phenotyp...

High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy

Standard

High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. / Tsourlakis, M C; Delmo Walter, Eva Maria; Quaas, A; Graefen, M; Huland, H; Simon, R; Sauter, G; Steurer, S; Schlomm, T; Minner, S.

In: PROSTATE CANCER P D, Vol. 16, No. 2, 01.06.2013, p. 159-64.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tsourlakis, MC, Delmo Walter, EM, Quaas, A, Graefen, M, Huland, H, Simon, R, Sauter, G, Steurer, S, Schlomm, T & Minner, S 2013, 'High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy', PROSTATE CANCER P D, vol. 16, no. 2, pp. 159-64. https://doi.org/10.1038/pcan.2012.50

APA

Tsourlakis, M. C., Delmo Walter, E. M., Quaas, A., Graefen, M., Huland, H., Simon, R., Sauter, G., Steurer, S., Schlomm, T., & Minner, S. (2013). High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. PROSTATE CANCER P D, 16(2), 159-64. https://doi.org/10.1038/pcan.2012.50

Vancouver

Tsourlakis MC, Delmo Walter EM, Quaas A, Graefen M, Huland H, Simon R et al. High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy. PROSTATE CANCER P D. 2013 Jun 1;16(2):159-64. https://doi.org/10.1038/pcan.2012.50

Bibtex

@article{ff1ea5d6b1654e8ab960dfac2fdbf21d,
title = "High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy",
abstract = "BACKGROUND: Neuron-glia-related cell-adhesion molecule (Nr-CAM) is another potential membrane-bound target molecule for specific prostate cancer therapy. The role of Nr-CAM in normal and neoplastic prostate tissue has not been extensively studied. The aim of our study is to evaluate the prevalence of Nr-CAM expression in prostate cancer and to explore its association with phenotype and clinical disease course.METHODS: A preexisting tissue microarray including more than 3000 prostate cancers that underwent prostatectomy at our center with clinical follow-up data was used. The tissue microarray (TMA) was immunhistochemically stained for Nr-CAM.RESULTS: A total of 2883 (88.4%) of tumor samples were interpretable in our TMA analysis. Membranous Nr-CAM staining was seen in 1418 (49.2%) of 2883 analyzable cases. According to predefined criteria, staining was considered weak in 778 (27.0%), moderate in 412 (14.3%) and strong in 228 (7.9%) cancers. Significant associations were found with pathological tumor stage (P=0.0015), Gleason grade (P=0.0003), nodal stage (P=0.0061), preoperative PSA (P=0.0138) and prolonged PSA recurrence-free survival (P<0.0001).CONCLUSIONS: Nr-CAM expression is frequent in prostate cancer. High level of Nr-CAM expression is associated with favorable tumor phenotype and reduced risk of PSA recurrence. The abundant presence of Nr-CAM in prostate cancer epithelium makes Nr-CAM a potential target of therapy.",
keywords = "Aged, Cell Adhesion Molecules, Disease-Free Survival, Humans, Kallikreins, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, Phenotype, Prognosis, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk, Tissue Array Analysis",
author = "Tsourlakis, {M C} and {Delmo Walter}, {Eva Maria} and A Quaas and M Graefen and H Huland and R Simon and G Sauter and S Steurer and T Schlomm and S Minner",
year = "2013",
month = jun,
day = "1",
doi = "10.1038/pcan.2012.50",
language = "English",
volume = "16",
pages = "159--64",
journal = "PROSTATE CANCER P D",
issn = "1365-7852",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy

AU - Tsourlakis, M C

AU - Delmo Walter, Eva Maria

AU - Quaas, A

AU - Graefen, M

AU - Huland, H

AU - Simon, R

AU - Sauter, G

AU - Steurer, S

AU - Schlomm, T

AU - Minner, S

PY - 2013/6/1

Y1 - 2013/6/1

N2 - BACKGROUND: Neuron-glia-related cell-adhesion molecule (Nr-CAM) is another potential membrane-bound target molecule for specific prostate cancer therapy. The role of Nr-CAM in normal and neoplastic prostate tissue has not been extensively studied. The aim of our study is to evaluate the prevalence of Nr-CAM expression in prostate cancer and to explore its association with phenotype and clinical disease course.METHODS: A preexisting tissue microarray including more than 3000 prostate cancers that underwent prostatectomy at our center with clinical follow-up data was used. The tissue microarray (TMA) was immunhistochemically stained for Nr-CAM.RESULTS: A total of 2883 (88.4%) of tumor samples were interpretable in our TMA analysis. Membranous Nr-CAM staining was seen in 1418 (49.2%) of 2883 analyzable cases. According to predefined criteria, staining was considered weak in 778 (27.0%), moderate in 412 (14.3%) and strong in 228 (7.9%) cancers. Significant associations were found with pathological tumor stage (P=0.0015), Gleason grade (P=0.0003), nodal stage (P=0.0061), preoperative PSA (P=0.0138) and prolonged PSA recurrence-free survival (P<0.0001).CONCLUSIONS: Nr-CAM expression is frequent in prostate cancer. High level of Nr-CAM expression is associated with favorable tumor phenotype and reduced risk of PSA recurrence. The abundant presence of Nr-CAM in prostate cancer epithelium makes Nr-CAM a potential target of therapy.

AB - BACKGROUND: Neuron-glia-related cell-adhesion molecule (Nr-CAM) is another potential membrane-bound target molecule for specific prostate cancer therapy. The role of Nr-CAM in normal and neoplastic prostate tissue has not been extensively studied. The aim of our study is to evaluate the prevalence of Nr-CAM expression in prostate cancer and to explore its association with phenotype and clinical disease course.METHODS: A preexisting tissue microarray including more than 3000 prostate cancers that underwent prostatectomy at our center with clinical follow-up data was used. The tissue microarray (TMA) was immunhistochemically stained for Nr-CAM.RESULTS: A total of 2883 (88.4%) of tumor samples were interpretable in our TMA analysis. Membranous Nr-CAM staining was seen in 1418 (49.2%) of 2883 analyzable cases. According to predefined criteria, staining was considered weak in 778 (27.0%), moderate in 412 (14.3%) and strong in 228 (7.9%) cancers. Significant associations were found with pathological tumor stage (P=0.0015), Gleason grade (P=0.0003), nodal stage (P=0.0061), preoperative PSA (P=0.0138) and prolonged PSA recurrence-free survival (P<0.0001).CONCLUSIONS: Nr-CAM expression is frequent in prostate cancer. High level of Nr-CAM expression is associated with favorable tumor phenotype and reduced risk of PSA recurrence. The abundant presence of Nr-CAM in prostate cancer epithelium makes Nr-CAM a potential target of therapy.

KW - Aged

KW - Cell Adhesion Molecules

KW - Disease-Free Survival

KW - Humans

KW - Kallikreins

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Phenotype

KW - Prognosis

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Risk

KW - Tissue Array Analysis

U2 - 10.1038/pcan.2012.50

DO - 10.1038/pcan.2012.50

M3 - SCORING: Journal article

C2 - 23338556

VL - 16

SP - 159

EP - 164

JO - PROSTATE CANCER P D

JF - PROSTATE CANCER P D

SN - 1365-7852

IS - 2

ER -